OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
December 19, 2013
ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.
Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.
CMC Biologics and OnoSynergy form an agreement from cell-line development.
Pfizer appoints management changes to take effect in 2014.
December 18, 2013
Operator training, preventive maintenance, and regularly scheduled calibration help prevent the manufacture of off-weight tablets.
Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.
December 12, 2013
BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.
Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).
December 06, 2013
Alvotech plans investment in biosimilars portfolio and manufacturing facility.
December 04, 2013
Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing